Skip to main content
Clinical Trials/NCT00474214
NCT00474214
Completed
Not Applicable

Safety And Feasibility of Early DischargE - a Prospective And Randomized Trial of Low-risk Primary PCI Patients (The SAFE-DEPART Trial)

Hamilton Health Sciences Corporation1 site in 1 country54 target enrollmentJanuary 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
Hamilton Health Sciences Corporation
Enrollment
54
Locations
1
Primary Endpoint
Safety: All-cause mortality
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this study is to determine if early hospital discharge (at 48-72 hours), is feasible, safe, cost-effective, and/or improves compliance with medications, positive lifestyle changes and quality-of-life, in low-risk patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (primary PCI).

Detailed Description

Patients with acute ST-segment elevation myocardial infarction (STEMI) have traditionally been hospitalized for at least 5-7 days to monitor for serious complications, including heart failure, arrhythmias, re-infarction and death. With the advent of primary percutaneous coronary intervention (PCI) as the treatment of choice for STEMI, fewer patients are completing their infarcts and the incidence of complications is decreasing. The Zwolle Primary PCI Index is one of several externally validated risk scores that can be used to identify low-risk primary PCI patients who can safely be discharged at 48-72 hours. Recent reviews have found that a majority of primary PCI patients with risk scores that deem them "low-risk" are kept in hospital longer than predicted by these scores. SAFE-DEPART is a trial where low-risk primary and rescue PCI patients will be randomized either to an intervention arm (early hospital discharge, early outpatient follow-up with a nurse practitioner) or to standard of care (no recommended discharge date, no outpatient follow-up with a nurse practitioner). At 6 weeks time, a blinded research assistant will contact patients and collect data on feasibility, safety, quality-of-life, and cost-effectiveness outcomes.

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
December 2007
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patient with ST-elevation myocardial infarction (STEMI)
  • Treatment with either primary or rescue PCI
  • Zwolle risk score \<= 3

Exclusion Criteria

  • Developed MI while in hospital for another reason
  • Time from angioplasty to enrollment \> 24 hours

Outcomes

Primary Outcomes

Safety: All-cause mortality

Time Frame: 6 weeks

Safety: Readmission for any of CHF, unstable angina, arrhythmia, re-infarction, revascularization, stroke, or major bleeding requiring transfusion

Time Frame: 6 weeks

Feasibility: Proportion of patients in the intervention group discharged within 72 hours ("feasible" if >= 70%)

Feasibility: Proportion of patients in the intervention group who saw nurse practitioner within 3 days of discharge ("feasible" if >= 80%)

Feasibility: Proportion of patients in the intervention group who saw nurse practitioner within 5 days of discharge ("feasible" if >= 90%)

Secondary Outcomes

  • Quality of life, as measured by the SF-36 questionnaire(6 weeks)
  • Compliance with medications(6 weeks)
  • Compliance with smoking cessation(6 weeks)
  • Attendance at first cardiac rehabilitation session(6 weeks)
  • Cost-effectiveness(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials